litlas
Log inCreate account

Eric F. Johnson

Active 1977–2024

104
Papers
22,080
Citations
77
h-index
103
i10-index

Citations

Citations per year for Eric F. Johnson1978: 3 citations1979: 7 citations1980: 3 citations1981: 8 citations1982: 15 citations1983: 11 citations1984: 23 citations1985: 12 citations1986: 18 citations1987: 33 citations1988: 54 citations1989: 99 citations1990: 107 citations1991: 95 citations1992: 110 citations1993: 99 citations1994: 74 citations1995: 93 citations1996: 72 citations1997: 81 citations1998: 96 citations1999: 137 citations2000: 113 citations2001: 99 citations2002: 134 citations2003: 117 citations2004: 234 citations2005: 203 citations2006: 254 citations2007: 281 citations2008: 262 citations2009: 293 citations2010: 328 citations2011: 296 citations2012: 240 citations2013: 284 citations2014: 202 citations2015: 249 citations2016: 186 citations2017: 176 citations2018: 179 citations2019: 445 citations2020: 501 citations2021: 437 citations2022: 321 citations2023: 255 citations2024: 376 citations2025: 203 citations2026: 12 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,724 citing papers, 33.3% of this breakdownChina: 743 citing papers, 9.1% of this breakdownUnited Kingdom: 650 citing papers, 8% of this breakdownGermany: 449 citing papers, 5.5% of this breakdownFrance: 336 citing papers, 4.1% of this breakdownAustralia: 268 citing papers, 3.3% of this breakdownJapan: 264 citing papers, 3.2% of this breakdownCanada: 231 citing papers, 2.8% of this breakdownItaly: 219 citing papers, 2.7% of this breakdownIndia: 191 citing papers, 2.3% of this breakdownSwitzerland: 179 citing papers, 2.2% of this breakdownNetherlands: 137 citing papers, 1.7% of this breakdown
0%33.3%Other 21.8%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology32.1%
  • Medicine31.1%
  • Pharmacology, Toxicology and Pharmaceutics19.9%
  • Computer Science6.8%
  • Chemistry2.5%
  • Environmental Science2.3%
  • Other5.3%

Topics

  • Pharmacogenetics and Drug Metabolism8.7%
  • Computational Drug Discovery Methods5.7%
  • Drug Transport and Resistance Mechanisms4.1%
  • PARP inhibition in cancer therapy3%
  • Cell death mechanisms and regulation2.3%
  • Peroxisome Proliferator-Activated Receptors2.2%
  • Other74%

Coauthors

All papers

Open in search
  1. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

    Authors: Christin Tse, Alexander R. Shoemaker, Jessica Adickes, Mark G. Anderson, Jun Chen, Sha Jin, Eric F. Johnson, Kennan C. Marsh, Michael J. Mitten, Paul Nimmer, Lisa Roberts, Stephen K. Tahir, Xiao Yu, Xiufen Yang, Haichao Zhang, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore - Cancer Research 2008 cited by 1,962

  2. ABC transporters: the power to change

    Authors: Douglas C. Rees, Eric F. Johnson, Oded Lewinson - Nature Reviews Molecular Cell Biology 2009 cited by 1,446

  3. Navigating the kinome

    Authors: James T. Metz, Eric F. Johnson, Niru B. Soni, Philip J. Merta, Lemma Kifle, Philip J. Hajduk - Nature Chemical Biology 2011 cited by 308

  4. PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

    Authors: Todd A. Hopkins, William B. Ainsworth, Paul A. Ellis, Cherrie K. Donawho, Enrico L. DiGiammarino, Sanjay C. Panchal, Vivek C. Abraham, Mikkel A. Algire, Yan Shi, Amanda M. Olson, Eric F. Johnson, Julie L. Wilsbacher, David Maag - Molecular Cancer Research 2018 cited by 256

  5. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer

    Authors: Shikhar Sharma, Chi‐Yeh Chung, Sean Uryu, Jelena Petrovic, Joan Cao, Amanda J. Rickard, Nataliya Nady, S.E. Greasley, Eric F. Johnson, Oleg Brodsky, Showkhin Khan, Hui Wang, Zhenxiong Wang, Yong Zhang, Konstantinos Tsaparikos, Lei Chen, Anthony Mazurek, John D. Lapek, Pei‐Pei Kung, Scott C. Sutton, Paul Richardson, Eric C. Greenwald, Shinji Yamazaki, Rhys Jones, Karen A. Maegley, Patrick Bingham, Hieu Lam, Alexandra E. Stupple, Aileen Kamal, Anderly C. Chüeh, Anthony N. Cuzzupe, Benjamin J. Morrow, Bin Ren, Catalina Carrasco‐Pozo, Chin Wee Tan, Dharmesh D. Bhuva, Elizabeth Allan, Elliot Surgenor, François Vaillant, Havva Pehlivanoglu, Hendrik Falk, James R. Whittle, Janet Newman, Joseph Cursons, Judy P. Doherty, Karen L. White, Laura MacPherson, Mark Devlin, Matthew L. Dennis, Meghan Hattarki, Melanie de Silva, Michelle A. Camerino, Miriam Butler, Olan Dolezal, Patricia A. Pilling, Richard C. Foitzik, Paul A. Stupple, H. Rachel Lagiakos, Scott R. Walker, Soroor Hediyeh-zadeh, Stewart D. Nuttall, Sukhdeep K. Spall, Susan A. Charman, Theresa Connor, Thomas S. Peat, Vicky M. Avery, Ylva E. Bozikis, Yuqing Yang, Ming Zhang, Brendon J. Monahan, Anne K. Voss, Tim Thomas, Ian P. Street, Sarah‐Jane Dawson, Mark A. Dawson, Geoffrey J. Lindeman, Melissa J. Davis, Jane E. Visvader, Thomas A. Paul - Cell chemical biology 2023 cited by 69

  6. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

    Authors: Junichiro Yuda, Christine Will, Darren C. Phillips, Linu Abraham, Cory Alvey, Abraham Avigdor, Wayne R. Buck, Lauren M. Besenhofer, Erwin R. Boghaert, Dong Cheng, Dan Cojocari, Kelly Doyle, Terkel Hansen, Kevin Y. Huang, Eric F. Johnson, Andrew S. Judd, Russell A. Judge, J. Cory Kalvass, Aaron Kunzer, Lloyd T. Lam, Rachel Li, Ruth L. Martin, Anthony Mastracchio, Mike Mitten, Adam M. Petrich, Jin Wang, James E. Ward, Haichao Zhang, Xilu Wang, Johannes Wolff, Katherine M. Bell‐McGuinn, Andrew J. Souers - Communications Medicine 2023 cited by 66

  7. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

    Authors: Todd A. Hopkins, Yan Shi, Luis E. Rodrı́guez, Larry R. Solomon, Cherrie K. Donawho, Enrico L. DiGiammarino, Sanjay C. Panchal, Julie L. Wilsbacher, Wenqing Gao, Amanda M. Olson, DeAnne Stolarik, Donald J. Osterling, Eric F. Johnson, David Maag - Molecular Cancer Research 2015 cited by 267

  8. Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1

    Authors: Rebecca A. Gallego, Louise Bernier, Hui Chen, Sujin Cho-Schultz, Loanne Chung, Michael R. Collins, Matthew Del Bel, Jeff Elleraas, Cinthia Costa Jones, Ciarán N. Cronin, Martin P. Edwards, Xu Fang, Timothy S. Fisher, Mingying He, Jacqui Hoffman, Ruiduan Huo, Mehran Jalaie, Eric F. Johnson, Ted W. Johnson, Robert S. Kania, Manfred Kraus, Jennifer Lafontaine, Phuong Le, Tongnan Liu, Michael Maestre, Jean Matthews, Michele McTigue, Nichol Miller, Qiming Mu, Xulong Qin, Shijian Ren, Paul Richardson, Allison Rohner, Neal W. Sach, Li Shao, Graham Smith, Ruirui Su, Bin Sun, Sergei Timofeevski, Phương Thu Trần, Shuiwang Wang, Wei Wang, Ru Zhou, JinJiang Zhu, Sajiv K. Nair - Journal of Medicinal Chemistry 2023 cited by 35

  9. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

    Authors: Cherrie K. Donawho, Yan Luo, Yanping Luo, Thomas D. Penning, Joy Bauch, Jennifer J. Bouska, Velitchka Bontcheva-Diaz, Bryan F. Cox, Theodore L. DeWeese, Larry E. Dillehay, Debra C. Ferguson, Nayereh Ghoreishi‐Haack, David R. Grimm, Ran Guan, Edward K. Han, Rhonda R. Holley-Shanks, Boris Hristov, Kenneth B. Idler, Ken Jarvis, Eric F. Johnson, Lawrence Kleinberg, Vered Klinghofer, Loren Lasko, Xuesong Liu, Kennan C. Marsh, Thomas McGonigal, Jonathan A. Meulbroek, Amanda M. Olson, Joann P. Palma, Luis E. Rodrı́guez, Yan Shi, Jason Stavropoulos, Alan C. Tsurutani, Gui‐Dong Zhu, Saul H. Rosenberg, Vincent L. Giranda, David J. Frost - Clinical Cancer Research 2007 cited by 773

  10. The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution

    Authors: Jason K. Yano, Michael R. Wester, G. Schoch, Keith J. Griffin, C.D. Stout, Eric F. Johnson - Journal of Biological Chemistry 2004 cited by 699

  11. Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer

    Authors: Thomas D. Penning, Gui‐Dong Zhu, Viraj B. Gandhi, Jianchun Gong, Xuesong Liu, Yan Shi, Vered Klinghofer, Eric F. Johnson, Cherrie K. Donawho, David J. Frost, Velitchka Bontcheva-Diaz, Jennifer J. Bouska, Donald J. Osterling, Amanda M. Olson, Kennan C. Marsh, Yan Luo, Vincent L. Giranda - Journal of Medicinal Chemistry 2008 cited by 269

  12. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

    Authors: Tea Pemovska, Eric F. Johnson, Mika Kontro, Gretchen A. Repasky, Jeffrey Chen, Peter A. Wells, Ciarán N. Cronin, Michele McTigue, Olli Kallioniemi, Kimmo Porkka, Brion W. Murray, Krister Wennerberg - Nature 2015 cited by 240

  13. Structural Characterization of Human Cytochrome P450 2C19

    Authors: R. Leila Reynald, Stefaan Sansen, C.D. Stout, Eric F. Johnson - Journal of Biological Chemistry 2012 cited by 133

  14. Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.

    Authors: Benedito A. Carneiro, Ruth Perets, Afshin Dowlati, Patricia LoRusso, Kan Yonemori, Lei He, Wijith Munasinghe, Behnam Noorani, Eric F. Johnson, Jon Zugazagoitia - Journal of Clinical Oncology 2023 cited by 18

  15. Aminopyridine-Based c-Jun N-Terminal Kinase Inhibitors with Cellular Activity and Minimal Cross-Kinase Activity

    Authors: Bruce G. Szczepankiewicz, Christi Kosogof, Lissa T.J. Nelson, Gang Liu, Bo Liu, Hongyu Zhao, Michael D. Serby, Zhili Xin, Mei Liu, Rebecca J. Gum, Deanna L. Haasch, Sanyi Wang, Jill E. Clampit, Eric F. Johnson, Thomas Lübben, Michael A. Stashko, Edward T. Olejniczak, Chaohong Sun, Sarah A. Dorwin, Kristi Haskins, Cele Abad‐Zapatero, Elizabeth H. Fry, Charles W. Hutchins, Hing L. Sham, Cristina M. Rondinone, James M. Trevillyan - Journal of Medicinal Chemistry 2006 cited by 160

  16. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection

    Authors: Martin Holdener, Edith Hintermann, Monika Bayer, Antje Rhode, Evelyn Rodrigo, Gudrun Hintereder, Eric F. Johnson, Frank J. Gonzalez, Josef Pfeilschifter, Michael P. Manns, Matthias von Herrath, Urs Christen - The Journal of Experimental Medicine 2008 cited by 195

  17. Crystal Structure of CYP24A1, a Mitochondrial Cytochrome P450 Involved in Vitamin D Metabolism

    Authors: Andrew J. Annalora, David B. Goodin, Wen‐Xu Hong, Qinghai Zhang, Eric F. Johnson, C.D. Stout - Journal of Molecular Biology 2009 cited by 177

  18. Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation

    Authors: Eric F. Johnson, Michele McTigue, Rebecca A. Gallego, Ted W. Johnson, Sergei Timofeevski, Michael Maestre, Timothy S. Fisher, Robert S. Kania, Sansana Sawasdikosol, Steven J. Burakoff, Ciarán N. Cronin - Journal of Biological Chemistry 2019 cited by 30

  19. The P450 Superfamily: Update on New Sequences, Gene Mapping, and Recommended Nomenclature

    Authors: Daniel W. Nebert, David R. Nelson, Minor J. Coon, Ronald W. Estabrook, René Feyereisen, Yoshiaki Fujii‐Kuriyama, Frank J. Gonzalez, F. Peter Guengerich, I. C. Gunsalus, Eric F. Johnson, JOHN C. LOPER, Ryo Sato, Michael R. Waterman, David J. Waxman - DNA and Cell Biology 1991 cited by 1,095

  20. Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2

    Authors: Stefaan Sansen, Jason K. Yano, R. Leila Reynald, G. Schoch, Keith J. Griffin, C.D. Stout, Eric F. Johnson - Journal of Biological Chemistry 2007 cited by 477

  21. Microbial ferric iron reductases

    Authors: Imke Schröder, Eric F. Johnson, Simon de Vries - FEMS Microbiology Reviews 2003 cited by 320

  22. The High-Affinity E. coli Methionine ABC Transporter: Structure and Allosteric Regulation

    Authors: Neena S. Kadaba, Jens T. Kaiser, Eric F. Johnson, Allen Lee, Douglas C. Rees - Science 2008 cited by 223

  23. Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer

    Authors: Rebecca A. Gallego, Sujin Cho-Schultz, Matthew Del Bel, Anne‐Marie Dechert‐Schmitt, Joyann S. Donaldson, Mingying He, Mehran Jalaie, Rob Kania, Jean Matthews, Michele McTigue, Jamison B. Tuttle, Hud Risley, Dahui Zhou, Ru Zhou, Omar Ahmad, Louise Bernier, Simon Berritt, John Braganza, Zecheng Chen, Julie Cianfrogna, Michael R. Collins, Cinthia Costa Jones, Ciarán N. Cronin, Carl Davis, Klaus Dress, Martin P. Edwards, William Farrell, Scott P. France, Nicole Grable, Eric F. Johnson, Ted W. Johnson, Rhys Jones, Thomas Knauber, Jennifer Lafontaine, Richard P. Loach, Michael Maestre, Nichol Miller, Mark A. Moen, Sébastien Monfette, Peter Morse, Andrew R. Nager, Mark Niosi, Paul Richardson, Allison Rohner, Neal W. Sach, Sergei Timofeevski, Joseph W. Tucker, Beth C. Vetelino, Lei Zhang, Sajiv K. Nair - Journal of Medicinal Chemistry 2024 cited by 19

  24. Peroxisome Proliferator Activated Receptor-α Expression in Human Liver

    Authors: Colin N.A. Palmer, Mei-H. Hsu, Keith J. Griffin, Judy L. Raucy, Eric F. Johnson - Molecular Pharmacology 1998 cited by 416